According to researchers at Semmelweis University, not only inflammation, but also sleep disorders, depression, obesity, and smoking may sustain persistent rheumatic symptoms. In their publications in the journals Nature Reviews Rheumatology and The Lancet Rheumatology, they also proposed a model that can help identify and treat the true causes of symptoms in time.

With colorectal cancer a growing concern among younger people, the American Cancer Society has endorsed two new types of stool tests to encourage people to get screened while also recommending a limited role for new blood tests many patients find appealing.

The American Cancer Society (ACS) today released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 and continue through age 75 for those with a life expectancy greater than 10 years. However, ACS is now adding guidelines for a blood-based screening test taken in a doctor’s office, as well as one updated and one new at-home screening option that looks for hidden blood and molecular markers in stool samples. The move reflects advances in disease detection and a critical shift in public health strategy to expand screening options and lower barriers to access. The update is published in a report in CA: A Cancer Journal for Clinicians, the flagship journal of ACS.

While virtual-reality path integration (VR-PI) may reveal subtle changes that precede the onset of clinical cognitive symptoms, the association between PI performance and structural brain changes remains unclear. Now, researchers have demonstrated that poor PI performance is linked to accelerated cortical thinning in several brain regions and is tied to key blood biomarkers of neurodegeneration. The findings suggest that VR navigation tasks may offer a non-invasive approach for early detection of neurodegenerative diseases.

Traumatic brain injury (TBI) affects millions worldwide, yet effective treatments remain limited. A new review outlines how stem cell-based therapies can promote brain repair by reducing inflammation, supporting neural regeneration, and restoring neural function. It also highlights emerging strategies such as exosome-based therapies and biomaterial scaffolds. While early clinical trials and preclinical findings are encouraging, translating these advances into reliable clinical treatments remains a critical next step.